J. Wang

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K. Park, Johan Vansteenkiste, Ki Hyeong Lee et al. · Annals of Oncology · 2020 · 114 citations · Full text

Medicine, Cancer Biology, Oncology +11

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Ying Cheng, Q. Wang, K. Li et al. · Journal of Thoracic Oncology · 2018 · 59 citations · Full text

Medicine, Oncology, Pharmacology +9

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

Masahiro Tsuboi, Yi‐Long Wu, C Grohé et al. · Annals of Oncology · 2022 · 23 citations

Medicine, Oncology, Pharmacology +14

Deficiency of P‐selectin glycoprotein ligand‐1 is protective against the prothrombotic effects of interleukin‐1β

Hui Wang, Kyle Kleiman, J. Wang et al. · Journal of Thrombosis and Haemostasis · 2015 · 12 citations · Full text

Veterinary Medicine, Immunology, Hemostasis +6

1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC

Shun Lü, Yunfang Yu, Xiaoling Yu et al. · Annals of Oncology · 2020 · 10 citations

Medicine, Oncology, Pharmacology +11